

REFERENCES

Abbot, B.; Young, D.S. and Burtis, A. (1984):

Creatine kinase in **Kaplan, A.** Clinical chemistry. The C.V. Mosby Co. St Louis, Toronto, Princeton: 1112 –1116.

Ahijevych, K. and Wewers, M.E. (2003):

Passive smoking and vascular disease. J. Cardiovasc. Nurs.; 18: 69 – 74.

Alpert, J.E. and Fova, M.; (1997):

Nutrition and depression: the role of folate. Nutr. Rev.; 55: 145 – 9.

Alpert, J.E.; Mischoulon, D.; Nierenberg, A.A. and Fova, M. (2000):

Nutrition and depression: focus on folate. Nutrition.; 16: 544 – 81.

Ambrosi, P.; Rolland, P.H.; Bodard, H.; Charpiot, P.; Guisgand, G.; Friggi, A.; Habib, G.; Garcon, D. and Luccioni, R. (1999):

Effect of folate supplementation in hyperhomocysteinemic Pigs, J. Am. Coll. Cardiol.; 34 : 274 – 9.

Anderson, A.; Brattstrom, L.; Israelsson, B.; Isaksson, A.; Hamfelt, A. and Hultberg, B. (1992):

Plasma homocysteine before and after methionine loading with regard to age, gender and menopausal status. Eur. J. Clin. Investing.; 22: 79 – 87.

Anversa, P. and Sonnenblick, E.H. (1990):

Ischemic cardiomyopathy: pathophysiologic mechanisms. Prog. Cardiovasc. Dis.; 33: 49 – 70.

Apeland, T.; Mansoor, M.A. and Stranjord, R.E. (2001):

Antiepileptic drugs as independent predictor of plasma total homocysteine levels. *Epilepsy Res.*; 47(1-2): 27– 35.

Armistag, P. (1983):

Statistical methods. In medical research. Blackwell scientific publications, Oxford, London.

Bailey, L.B. (1995):

Alcohol and folate interactions: clinical implication in Folate in Health and Disease. Textbook, p. 313 – 27.

Barret-Connor, E. and Bush, T.L. (1991):

Estrogen and coronary heart disease in women. *JAMA.*; 256: 1861-7.

Barton, M.; Carmona, B.; Morawietz, H.; Goettsch, W. and Hillen, C.C. (2000):

Obesity is associated with tissue specific activation of renal angiotensin converting enzyme, in vivo evidence for regulatory role of endothelium. *Hypertension.*; 35: 329 – 36.

Barua, R.S.; Ambrose, J.A.; Eales- Reynolds, L.J.; DeVoe H.C.; Zervas, J.G. and Saha, D.C. (2002):

Heavy and Light cigarette smokers have similar dysfunction of endothelial vasoregulatory activity: an in vivo and in vitro correlation. *J. Am. Coll. Cardiol.*; 39: 1758 – 63.

Belchetz, P.E. (1994):

Hormonal treatment of postmenopausal women. *N. Engl. J. Med.*; 330: 1062.

Bellamy, M.F.; McDowell, I.F.; Ramsey, M.W.; Brownlee, M.; Bones, C.; Newcombe, R.G., and Lewis, M.J. (1998):

Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. *Circulation*; 98 (18): 1848 – 52.

Bertam, G.K. (1995):

Adrenergic receptor and sympathomimetic drugs. Basic clinical pharmacology. Textbook, 6th ed., ch. 9, p.124.

Blom, H.J. (1995):

Lipid peroxidation and susceptibility of low density lipoprotein to in vitro oxidation in hyperhomocysteinemia. *Eur. J. clin. Invest.* 25: 149 – 54.

Boers, G. (1994):

Hyperhomocysteinemia: a newly recognized risk factor for vascular disease. *Neth. J. Med.*; 45: 34 – 41.

Boger, R.H.; Bode-Boger, S.M.; Sydow, K.; Heistod, D.D. and Lentz, S.R. (2000):

Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocysteinemia or hypercholesterolemia. *Arterioscler. Thromb. Vasc. Biol.*; 20: 557- 64.

Bostom, A.G.; Jacques, P.F. Nadeau, M.R.; Williams, R.R.; Ellison, R.C. and Selhub, J. (1995):

Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial result from NHLBI Family Heart Study. *Atherosclerosis*.; 116: 147 – 51.

Bottiglieri, T. (1996):

Folate, Vitamin B12 and neuropsychiatric disorders. *Nutr. Rev.*; 54 (12): 382 – 97.

Boushey, C.J.; Beresford, S.A.; Omenn, G.S. and Motulsky, A.G. (1995):

A quantities assessment of plasma homocysteine as a risk factor for vascular diseases: probable benefits of increasing folic acid intake. *JAMA.*; 274: 1049 – 57.

Bowman, B.A. and Russel, R.M. (2001):

Folate. *Present Knowledge In Nutrition. Textbook*, 8th ed.: 214 – 29.

Brattstrom, L. and Wilken, D.E. (2000):

Homocysteine and cardiovascular disease: cause or effect?. *Am. J. Clin. Nutr.*; 72 (2): 315 – 23.

Brouwer, I.A.; VanDusseldorp, M.; Duran, M.; Thomas, C.M.; Hautvast, J.G.; Eskes, T.K and Steegers- Theunissen, R.P. (1999):

Low dose folic acid supplementation does not influence plasma methionine concentration in young non- pregnant women. *Br. J. Nutr.*; 82 (2): 85 – 9.

Brydon, L.; Magid, K. and Steptoe, A. (2006):

Platelets, coronary heart disease and stress. *Brain Behav. Immun.*; 20 (2): 113 – 9.

Bunout, D.; Petermann, M.; Hirsch, S.; De La Maza, M.P.; Suazo, M.; Barrera, G. and Kauffman, R. (2000):

Low serum folate but normal homocysteine levels in patients with atherosclerotic vascular disease and matched healthy controls. *Nutrition.*; 16: 434 – 38.

Campbell, N.R. (1996):

How safe are folic acid supplements?. Arch. Intern. Med.; 156: 638 – 44.

Canto, J.G.; Shlipak, M.G.; Rogers, W.J.; Malmgren, J.A.; Frederick, P.D.; Lambrew, C.T.; Ornato, J.P.; Barron, H.V. and Kiefe, C.I. (2000):

Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. JAMA.; 283 (24): 3223 – 9.

Chan, M.; Soter, D. and Kow, W. (1987):

Effect of morphine on cardiovascular response to acute myocardial infarction in rats. Br. J. Pharm.; 90: 537– 43.

Chen, F.Y.; Guo, Y.H.; Gao, W.; Feng, X.H.; Chen, L. and Tang, C.S. (2006):

Effect of hyperhomocysteinemia on cardiac remodeling in rats. Beijing Pa xue Xue Bao.; 38 (2): 179 – 83.

Chernecky, C.C. and Berger, B.J. (1997):

Laboratory tests and diagnostic procedures. Textbook. P. 666.

Christen, W.G.; Ajani, U.A.; Glynn, R.J. and Henneken, C.H. (2000):

Blood levels of homocysteine and increased risk of cardiovascular disease: causal or casual?. Arch. Intern. Med.; 160: 422 – 34.

Churscinski, A.; Brede, M.E.; Meinel, L.; Lohse, M.J.; Kobilka, B.K. and Hein, L. (2001):

Differential distribution of B-adrenergic subtypes in blood vessels of knockout mice lacking B1- or B2- adrenergic receptors. Mol. Pharmacol.; 60: 955 – 62.

Collaboration, H.L.T. (1998):

Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. *BMJ*; 316: 894 – 8.

Collinson, P.O.; Chandler, H.A.; Stubbs, P.J. Moseley, D.S.; Lewis, D. and Simmons, M.D. (1995):

Measurement of serum troponin T, creatine kinase MB isoenzyme, and total creatine kinase following arduous physical training. *Ann. Clin. Biochem.*; 32: 450 – 3.

Constans, J.; Blann, A.D.; Resplandy, F.; Parrot, F.; Renard, M.; Seigneur, M.; Guerin, V.; Boisseau, M. and Conri, C. (1999):

Three months supplementation of hyperhomocysteinemic patients with folic acid and vitamin B6 improves biological markers of endothelial dysfunction. *Br. J. Haematol.*; 107 (4): 776 – 8.

Cooke, J.P. and Oka, R.K. (2002):

Does leptin cause vascular disease *Circulation.*; 106: 1904 – 5.

Crepaldi, G.; Tiengo, A. and Manzato, E. (1993):

The plurimetabolic syndrome in textbook of Diabetes, Obesity and Hyperlipidemias. Amsterdam, Netherlands Excerpta Medica, International congress series. chapter V, p. 1039.

Critchley, J.A. and Capewell, S. (2003):

Mortality risk reduction with smoking cessation in patient with coronary heart disease: systematic review. *JAMA.*; 290: 86 – 97.

Dardik, R.; Varon, D.; Tamarin, I.; Zivelin, A.; Salomon, O.; Shenkman, B. and Savion, N. (2000):

Homocysteine and oxidized low density lipoprotein enhanced platelet adhesion to endothelial cells under flow conditions: distinct mechanisms of thrombogenic modulation *thromb. Haemost.*; 83 (2): 338 – 44.

Davi, G.; Catalano, I.; Aversa, M.; Notarbartolo, A.; Strano, A.; Ciabattini, G. and Patrono, C. (1990):

Thromboxane biosynthesis and platelet function in type II diabetes mellitus. *N. Engl. J. Med.*; 322 (25): 1769 – 74.

deBree, A.; Verschuren, V.M.W.; Blom, H.J.; DeGraaf-Hess, A.; Trijbels, F.J.M. and Kromhout, D. (2001):

The homocysteine distribution : misjudging the burden. *J. Clin. Epidemiol.*; 54: 462 – 69.

Deedwania, P.C. (2003):

Diabetes and vascular disease: common link in the emerging epidemic of coronary artery disease. *Am. J. Cardiol.*; 91 (1): 68-77.

deJong, S.C.; Stehouwer, C.D.; Vanden Berg, M.; Vischer, U.M.; Rauwerda, J.A. and Emeis, J.J. (1997):

Endothelial marker proteins in hyperhomocysteinemia. *Thromb. Haemost.*; 78: 1332 – 37.

deWinter, R.J.; Koster, R.W.; Sturk, A. and Sanders, G.T. (1995):

Value of myoglobin, troponin T, and CK-MB mass in ruling out an acute myocardial infarction in the emergency room. *Circulation.*; 92: 3401 – 7.

DiMinno, G.; Davi, G.; Margaglione, M.; Cirillo, F.; Gradone, E.; Ciabattini, G.; Catalano, I.; Strisciuglio, P.; Andria, G. and Patrono, C. (1993):

Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. *J. Clin. Invest.*; 92: 1400 – 06.

Doshi, S.N.; McDowell, I.F.; Moat, S.J. Payne, N.; Durrant, H.J.; Lewis, M.J. and Goodfellow, J. (2002):

Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. *Circulation*; 105(1): 22 – 6.

Doshi, S.N.; McDowell, I.F.; Moat, S.J.; Lang, D.; Newcombe, R.G.; Kredan, M.B.; Lewis, M.J. and Goodfellow, J. (2001):

Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide? *Arterioscler. Thromb. Vasc. Biol.*; 21: 1196 – 1202.

Durand, P.; Lussier-Cacan, S.; and Blache, D. (1997):

Acute methionine load induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis and macrophage derived tissue factor activity in rats. *FASEB J.*; 11 (13): 1157 – 68.

Durand, P.; Prost, M. and Blache, D. (1996):

Pro-thrombotic effects of folic acid deficient diet in rat platelet and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids. *Atherosclerosis*. 121 (2): 231 – 43.

Eckel, R.H. and Krauss, R.M. (1998):

American Heart Association call to action: obesity as a major risk factor for coronary heart disease: AHA Nutrition Committee. *Circulation.*; 97, 2099 – 2100.

Emsley, A.M.; Jeremy, J.Y.; Gomes, G.N.; Angelini, G.D. and Plane, F. (1999):

Investigation of the inhibitory effect of homocysteine and copper on nitric oxide mediated relaxation of rat isolated aorta. *Br.J. pharmacol.*; 126 (4): 1034 – 40.

Ensminger, A.H.; Ensminger, M.E.; Konlande, J.E. and Robson, J.R. (1995):

Text book of the concise Encyclopedia of foods and nutrition: 367- 76.

Essien, F.B. and Wannberg, S.L. (1993):

Methionine but not folinic acid and vitamin B12 alters the frequency of neural tube defects in Axd mutant mice. J. Nutr., 123: 973 –74.

Evans, R.C.; Mejios, J.E.; Kulevish, J.; Fischer, V.W. and Muller, H.S. (1985):

Evaluation of a rat model for assessing intervention to salvage ischemic myocardium. Cardiovasc. Res.;19: 123.

Everts, B.; Karlson, B.W.; Wahrborg, P.; Hender, T. and Herlitz, J. (1996):

Localization of pain in suspected acute myocardial infarction in relation to final diagnosis, age and sex, and site and type of infarction. Heart Lung.; 25: 430 – 7.

Fenga, C.; Micali, E.; Cacciola, A.; Trimarchi, C. ad Germano, D. (2004):

Stressful life events and fibrinogen level in middle aged teachers. Psychopathology.; 73 (2): 64 – 8.

Finkelstein, J.D. (1990):

Methionine metabolism in mammals. J. Nutr Biochem.; 1: 228 – 37.

Fletcher, G.F.; Balady, C.G.; Blair, S.N.; Blumenthal, J.; Caspersen, C.; Chaitman, B.; Epstein, S.; Froelicher, S.S.; Froelicher, V.F.; Pina, I.L. and Pollock, M.L. (1996):

Statement on exercise: benefits and recommendation for physical activity programs for all Americans: a statement for health professionals by the committee on exercise and cardiac rehabilitation of the Council of Clinical Cardiology, American Heart Association. Circulation.; 94: 857.

Fonseca, V.; Guba, S.C. and Fink, L.M. (1999):

Hyperhomocysteinemia and the endocrine system: implication for atherosclerosis and thrombosis. *Endocrine Reviews*; 20 (5): 738.

Ford, E.S.; Byers, T.E. and Giles, W.H. (1998):

Serum folate chronic disease risk: findings from a cohort study of United States adults. *Int. J. Epidemiol.*; 27: 592 – 8.

Fowler, B. (2005):

Homocysteine--an independent risk factor for cardiovascular and thrombotic diseases. *Ther. Umsch.*; 62(99): 641 – 6.

Freyburger, G.; Labrousse, S.; Sassoust, G.; Rouanet, F. Javorschi, S. and Parrot, F. (1997):

Mild hyperhomocysteinemia and hemostatic factors in patients with arterial vascular diseases. *Thromb. Haemost.*; 77 (3): 466 – 71.

Fridman, J.M. and Halaas J.L. (1998):

Leptin and regulation of body weight in normals. *Nature.*; 395: 763 – 70.

Fujimoto, S.; Togane, Y.; Matsuzaki, C.; Yamashina, S.; Nakano, H.; Yamazaki, J. and Yoshino, G. (2003):

Effect of long-term administration of methionine on vascular endothelium in rabbits. *Nutr. Metab. Cardiovasc. Dis.*; 13 (1): 20-7.

Fuster, V.; Aleander, R.W.; Rourke, R.A.; Roberts, R.; King III, S.B. and Ellens, H.J. (2001):

Hurst's The Heart. Textbook, Vol.1, 10th ed., p. 1131, 1237.

Garg, U.C.; Zheng, Z.J.; Folsom, A.R.; Moyer, Y.S.; Tasi, M.Y.; McGovern, P. and Eckfeldt, J.H. (1997):

Short term and long term variability of plasma homocysteine measurement. *Clin. Chem.*; 43: 41 – 5.

Gerdes, V.E.; Hovinga, H.A.; tenCate, H.; Macgillavry, M.R.; Leijte, A.; Reitsma, P.H.; Brandjes, D.P. and Buller, H.R. (2004):

The Amsterdam vascular Medicine group. Homocysteine and markers of coagulation and endothelial cell activation. J. Thromb. Haemost.; 2 (3): 445 – 51.

Gluek, C.J.; Shaw, P.; Lang, J.E.; Tracy, T.S. Sieve-Smith, L. and Wang, Y. (1995):

Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am. J. Cardiol.;75: 132 - 6.

Goodacre, S.; Locker, T.; Morris, F. and Campbell, S. (2002):

How useful are clinical features in the diagnosis of acute undifferentiated chest pain?. Acad. Emerg. Med.; 9: 203 – 8.

Gori, A.M.; Corsi, A.M.; Fedi, S.; Gazzini, A.; Sofi, F.; Bartali, B.; Bandinelli, S.; Gensini, G.F.; Abbate, R. and Ferrucci, L. (2005):

A proinflammatory state is associated with hyperhomocysteinemia in the elderly. Am. J.clin. Nutr.; 82 (2): 335 – 41.

Gornall, D.A. and Roth, S.N. (1996):

Serial myoglobin quantitation in the early assessment of myocardial damage: a clinical study. Clin. Biochem.; 29: 379 – 84.

Gould, A.L.; Rossouw, J.E.; Santanella, N.C.; Heyse, J.F. and Furberg, C.D. (1998):

Cholesterol reduction yields clinical benefits impact of statin trials. Circulation.; 97: 946 – 52.

Gregory, J. (2005):

Using the 12 lead ECG to assess acute coronary patients. Br. J. Nurs.; 14(21): 1135 – 46.

Grimm, D.; Elsner, D.; Schunkert, H.; Pfeifer, M.; Griesse, D.; Bruckschlegel, G.; Muders, F.; Riegger, G. A. and Kromer, E.P. (1998):

Development of heart failure following isoproterenol administration in the rat: the role of rennin angiotensin system. *Cardiovasc. Res.*; 37: 91 – 100.

Grundy, S.M. (2002):

Obesity, metabolic syndrome, and coronary atherosclerosis. *Circulation.*; 105: 2696 – 8.

Grundy, S.M.; Pasternak, R.; Greenland, P.; Smith, S. and Fuster, V. (1999):

Assessment of cardiovascular risk by use of multiple risk factor assessment equation: A statement for health care professionals from American Heart Association and American College of Cardiology. *Circulation.*;100: 1481 – 92.

Guerci, B.; Bohm, P.; Kearney –Schawartz, A.; Zannad, F. and Drouin, P. (2001):

Endothelial dysfunction and type 2 diabetes. *Diabetes Metab.*; 27 (4): 436 – 47.

Haffner, S.M.; Lehto, S.; Ronnema, T.; Pyroala, K. and Laakso, M. (1998):

Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. *N. Engl. J. Med.*; 339 (4): 229 – 234.

Hagar, H.H. (2002):

Folic acid and vitamin B12 supplementation attenuates isoprenaline-induced myocardial infarction in experimental hyperhomocysteinemic rats. *Pharmacol. Res.*; 46 (3): 213 – 9.

Hakim, A.A.; Curb. J.D.; Petrovitch, H.; Rodriguez, B.L.; Yano, K.; Ross, G.W.; White, L.R. and Abbot, R.D. (1999):

Effect of walking on coronary heart disease in elderly men. Circulation.; 100: 9 – 13.

Halcox, J.P.; Schenke, W.H.; Zalos, G.; Mincemoyer, R.; Prasad, A.; Waclawiw, M.A.; Nour, K.R. and Qyyumi, A.A. (2002):

Prognostic value of coronary vascular endothelial dysfunction. Circulation; 106: 653 – 8.

Hanratty, C.G.; McAuley, D.F.; McGrath, L.T.; Young, I.S. and Johnston, G.D. (2001):

Hyperhomocysteinemia in young adults is not associated with impaired endothelial function. Clin. Sci.; 100: 67 – 72.

Hardman, J.G.; Limbird, L.E. and Gilman, A.G. (2001):

Hematopoietic agents: growth factors, minerals and vitamins. Pharmacologic Basis of Therapeutics. Textbook 10th ed., p. 1487 – 1517.

Harpel, P.C.; Zhang, X. and Borth, W. (1996):

Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis. J. Nutr.; 126 : 1285s –1289s

Haynes, W.G. (2002):

Hyperhomocysteinemia, vascular function and atherosclerosis. Cardiovasc. Drugs Ther.; 16 (5): 391 – 9.

Heinke, J.W. (1998):

Oxidants and antioxidants in the pathogenesis of atherosclerosis: implication for the oxidized low density lipoprotein hypothesis. Atherosclerosis.; 141: 1 – 5.

Henderson, A.H. (1991):

Endothelium in control. *Br. Heart J.*; 56: 116 –25.

Herman, W. (2001):

The importance of hyperhomocysteinemia as a risk factor for diseases: an overview. *Clin. Chem. Lab. Med.*; 39 (8): 666 – 74.

Himari and Matsuura (1989):

A simple technique after occlusion and reperfusion of coronary artery in conscious rats. *Am. J. Physiol.* 256 (Heart Circ. Physiology); (25): H 1719 – H 1725.

Hoffmann, M.A.; Lalla, E.; Lu, Y.; Wolf, BM.; Tang, N.; Rao, V.; Kisiel, W.; Stern, D.M. and Schmidt, A.M. (2001):

Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in murine models. *J. clin. Invest.*; 107 (6): 675 – 83.

Holven, K.B.; Holm, T.; Aukrust, P.; Christensen, B.; Kjekshus, J.; Andreassen, A.K.; Gullestad, L.; Hagve, T.A.; Svilaas, A.; Ose, L. and Nenseter, M.S. (2001):

Effect of folic acid treatment on endothelium- dependent vasodilatation and nitric oxide derived end products in hyperhomocysteinemic subjects. *Am. J. Med.*; 110 (7): 536 – 42.

Hultberg, B.; Berglund, M.; Anderson, A. and Frank, A. (1993):

Elevated plasma homocysteine in alcoholism. *Alcohol Clin. Exp. Res.*; 17: 687 – 9.

Hung, J.; Beilby, J.P.; Knuiman, M.W. and Divitini, M. (2003):

Folate and vitamin B12 and risk of fatal cardiovascular disease: Cohort study from Busselton, Western Australia. *BMJ*; 326: 131.

Iwamoto, K.; Chein, C. and Kato L. (1987):

Effect of urethane anesthesia and age on organ blood flow in rats measured by hydrogen gas clearance method. *J. Pharmacobiodyn.*; 10(6): 280 – 4.

Jacobsen, D.W. (1996):

Determinants of hyperhomocysteinemia: a matter of nature and nurture. *Am. J. Clin. Nutr.*; 64: 641 – 2.

Jacques, P.F.; Bostom, A.G.; William, R.R.; Ellison, R.C.; Eckfeldt, J.H.; Rosenberg, I.H.; Selhub, J. and Rozen, R. (1996):

Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. *Circulation*; 93: 1, 7 – 9.

Jousilahti, P.; Vartiainen, E.; Tuomilehto, J. and Puska, P. (1999):

Sex, age, cardiovascular risk factors and coronary heart disease: prospective follow up study of 14.786 middle aged men and women in Finland. *Circulation.*; 99: 165 – 72.

Juhlin, L. and Olsson, M.J. (1997):

Improvement of vitiligo after oral treatment with vitamin B12 and folic acid and the importance of sun exposure. *Acta. Derm. Venereal.*; 77: 6, 640 – 2.

Julian, D.J. (1989):

Diseases of the heart. *Text book of cardiovascular Medicine*, p. 165, 325.

Kalra, D.K. (2004):

Homocysteine and cardiovascular disease. *Curr. Atheroscler. Rep.*; 6 (2): 101 – 6.

Kang, S.S.; Wong, P.W.K. and Malinow, M.R. (1992):

Hyperhomocysteinemia as a risk factor for occlusive vascular disease. *Annu. Rev. Nutr.*; 12: 279 – 98.

Kazemi, M.B. Eshraghian, K.; Omrani, G.R.; Lankarani, K.B. and Hosseini, E. (2006):

Homocysteine level and coronary artery disease. *Angiology.*; 57 (1): 9 – 14.

Khajuria, A. and Houston, D.S. (2000):

Induction of monocyte tissue factor expression by homocysteine: a possible mechanism for thrombosis. *Blood*; 96 (3): 966 – 72.

Kim, K.S.; Own, W.L.; Williams, D. and Adams-Campbell, L.L. (2000):

A comparison between BMI and conicity index on predicting coronary heart disease: The Framingham Heart study. *Ann. Epidemiol.*; 10 (7): 424 – 31.

Klerk, M.; Durga, J.; Schouten, E.G.; Kuft, C.; Kok, F.J. and Verhoef. P. (2005):

No effect of folic acid supplementation in the course of 1 year on haemostasis markers and C-reactive protein in other adults. *Thromb. Haemost.*; 94 (1): 96 – 100.

Knobler, H.; Savion, N.; Shenkman, B.; Kotev- Emeth, S. and Varon, D. (1998):

Shear- induced platelet patients. *Thromb. Res.*; 90: 181 –90.

Kosuge, M.; Kimura, K.; Ishikawa, T.; Ebina, T.; Hibi, K.; Tsukahara, K.; Kanna, M.; Iwahashi, N.; Okuda, J.; Nozawa, N.; Ozaki, H.; Yano, H.; Nakati, T.; Kusama, I. and Umemura, S. (2006):

Differences between men and women in terms of clinical features of ST-segment elevation of acute myocardial infarction. *Circ. J.*; 70(3): 222 – 6.

Kou, V. and Nassisi, D. (2006):

Unstable and non ST-segment myocardial infarction: an evidence-based approach to management. Mt. Sinai J. Med.; 73(1): 449 – 68.

Koumann, A.J. and Molenaar, P. (1997):

Modulation of human cardiac function through 4 B-adrenoreceptor populations. Naunyn- Schmiedcberg's Arch. Pharmacol.; 335: 667 – 81.

Kumar, V.; Cotran, R. S. and Robbins, S.L. (1997):

Textbook of Basic Pathology. 6th ed., Ch. 11: 308 – 340.

Kung, S.H.; Hagstrom, J.N.; Cass, D.; Tai, S.J.; Lin, H.; Stafford, D.W. and High, K.A. (1998):

Human factor IX corrects the bleeding diathesis of mice with hemophilia B. Blood; 91 (3): 784 –90.

Lacy, F.; O'connor D.T. and Schmid- Schonbein, G.W. (1998):

Plasma hydrogen peroxide production in hypertensive and normotensive subjects at genetic risk of hypertension. J. Hypertens.; 16: 291 – 303.

Lakka, H.M.; Laakisonen, D.E.; Lakka, T.A.; Niskanen, K.K.; Kumpusalo, E.; Tuomilehto, J. and Salonen, J.T. (2002):

The metabolic syndrome and total and cardiovascular disease mortality in middle aged men. JAMA.; 288 (21): 2709 – 16.

Lander, K.; Hallqwst, J.; Reuterwall, C.; Ahlbam, A. and DeFire, V. (2001):

Family history of coronary heart disease, strong risk factor for myocardial infarction interacting with other risk factors: results from Stockholm Heart Epidemiology Program (SHEEP). Epidemiology.; 12 (2): 215 – 21.

Lang, D.; Kredan, M.B.; Moat, S.J.; Hussain, S.A.; Powell, C.A. and Bellamy, M.F. (2000):

Homocysteine induced inhibition of endothelium dependent relaxation in rabbit aorta: role for superoxide anions. *Arterioscler. Thromb. Vasc. Biol.*; 20 (2): 422 – 7.

Levinson, S.S. and Hobbs, G.A (1994):

Usefulness of various lactate dehydrogenase isoenzyme-1 profiles after acute myocardial infarction. *Ann. Clin. Lab. Sci.*; 24: 364 – 70.

Liao, J.K.; Shin, W.S.; Lee, W.Y. and Clark, S.L. (1995):

Oxidized low density lipoprotein decreases the expression of endothelial nitric oxide synthase. *J. Biol. Chem.*; 270: 319 – 24.

Lohse, M.J.; Engethardt, S. and Eschenhagen, T. (2003):

What is the role of B-adrenergic receptor signaling in heart failure. *Circ. Res.*; 93: 896.

Loka, T.; Tasaki, H.; Yashiro, A.; Yamashita, K.; Zozumi, K.; Tsotsui, M.; Kouzuma, R.; Okazaki, M. and Nakashima, Y. (2002):

Association between plasma lipoprotein(a) and endothelial dysfunction in normocholesterolemic and non-diabetic subjects with angiographically normal coronary arteries. *Circ. J.*; 66 (3): 267 – 71.

Lokaski, S.G. and Herrington, D.M. (2005):

Effect of hormone therapy on C-reactive protein and IL- 6 in postmenopausal women: a review article. *Climacteric.*; 8 (4): 317– 26.

Lonn, E.; Yusuf, S.; Arnold, M.J.; Sheridan, P. Pogue, J.; Micks, M.; McQueen, M.J.; Probstfield, J.; Fodor, G.; Held, C. and Genest, J. Jr. (2006):

Homocysteine lowering with folic acid and B- vitamins in vascular disease. *N. Engl. J. Med.*; 354 (15): 1567 – 77.

Lowel, H.; Dobson, A.; Keil, U.; Herman, B.; Hobbs, M.S.; Stewart, A.; Aristla, M.; Miettinen, H.; Mustaniemi, H. and Tuomilehto, J. (1993):

For the acute myocardial infarction register teams of Auckland, Augsburg, Bremen, FINMONICA, Newcastle and Perth. Coronary heart disease case fatality in four countries: a community study. *Circulation.*; 88: 2524 – 31.

Luo, F.; Liu, X.; Wang, S. and Chen, H. (2006):

Effect of homocysteine activation induced by collagen. *Nutrition*; 22 (1): 69 – 75.

Maccoss, M.J; Fukagawa, N.K and Matthews, D.E. (2001):

Measurement of intracellular sulfur amino acid metabolism in humans. *Am. J. Physiol. (Endocrinol. Metab.)*; 280: E 947 – E 955.

Malinow, M.R.; Duell, P.B.; Hess, D.L.; Anderson, P.H.; Kruger, W.D.; Phillipson, B.E.; Gluckman, R.A.; Block, P.C. and Upson, B.M. (1999):

Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. *N. Engl. J. Med.*; 338: 15, 1009 – 15.

Mangoni, A.A.; Arya, R.; Ford, E.; Asonganyi, B.; Sherwood, R.A.; Ouldred, E.; Swift, C.G. and Jackson, S.H. (2003):

Effect of folic acid supplementation on inflammatory and thrombogenic markers in chronic smokers. A randomized controlled trial. *Thromb. Res.*; 110 (1): 13-7.

Manrique, J.; Diaz, A.; Gavira, J.J.; Hernandez, A.; Pujante, D. and Errasti, P. (2005):

Preliminary results of the effect of treatment of hyperhomocysteinemia and its relationship with inflammation, coagulation status and endothelial function after renal transplantation. *Transplant. Proc.* 37 (9): 3782 – 4.

Marchioli, R.; Schweiyer, C.; Levantesi, G.; Tavazzi, L. and Valagussa, F. (2001):

Oxidant vitamins and prevention of cardiovascular disease: epidemiology and clinical trial data. *Lipids.*; 36 suppl.: S53 – 63.

Mason, J.B. and Miller, J.W. (1992):

The effects of vitamin B12, B6 and Folate on blood homocysteine levels. *Ann. Ny. Acad. Sci.*; 667: 197 – 204.

Matthias, D.; Becker, C.H.; Riezler, R. and Kindling, P.H. (1996):

Homocysteine induced arteriosclerosis – like alterations of the aorta in normotensive and hypertensive rats following application of high doses of methionine. *Atherosclerosis*; 122 (2): 201–16.

Mayer, E.L.; Jacobsen, D. and Robinson, K. (1996):

Homocysteine and coronary atherosclerosis. *Am. J. Coll. Cardiol.*; 27: 517 – 27.

Mazza, A.; Bossone, E.; Mazza, F. and Distane, A. (2004):

Homocysteine and cardiovascular risk. *Monaldi Arch. Chest Dis.*; 62 (1): 29 – 33.

McBride, P.E. (1992):

The health and consequence of smoking and cardiovascular diseases. *Med. Clin. North. Am.*; 76: 333 – 53.

McCully, K.S. (1969):

Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. *Am. J. Pathol.*; 56: 111 – 28.

McCully, K.S. (1993):

Chemical pathology of homocysteine. *Atherogenesis Anal Clin. Lab. sci.*; 23 (6): 477 – 93.

McCully, K.S. (2004):

Homocysteine, vitamins and prevention of vascular disease. *Mil. Med.*; 169 (4): 325 – 9.

Meenan, J.; O'Hallinan, E. and Scott, J. (1997):

Epithelial cell folate depletion occurs in neoplastic but not adjacent normal colon mucosa. *Gastroenterology*; 112(4): 1163 – 8.

Miller, A.L. and Kelly, G.S. (1997):

Homocysteine metabolism: nutritional modulation and impact on health and disease. *Alt. Med. Rev.*; 2 (4): 234 – 54.

Miller, J.W.; Nadeau, M.R.; Smith, D. and Selhub, J. (1994):

Vitamin B6 versus folate deficiency: comparison of response to methionine loading in rats. *Am. J. Clin. Nutr.*; 59: 1033 – 9.

Moat, S.J. and McDowell, I.F. (2005):

Homocysteine and endothelial function in human studies. *Semin. Vasc. Med.*; 5 (2): 172 – 82.

Morita, H.; Kurihara, H.; Yoshida, S.; Saito, Y.; Shindo, T.; Oh-hash, Y.; Kurihara, Y.; Yazaki, Y. and Nagai, R. (2001):

Diet-induced hyperhomocysteinemia exacerbates neointima formation in rat carotid arteries after balloon injury. *Circulation*; 103: 133.

Morita, H.; Taguchi, J.; Kurihari, H.; Kitaoka, M.; Kaneda, H.; Kurihara, Y.; Maemura, K.; Shindo, T. Minamino, T. and Ohno, M.(1997):
Genetic polymorphism of 5,10 methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease *Circulation*; 95: 2032 – 6.

Morrow, J.D. (2005):

Quantification of isoprostanes as incidence of oxidant stress and the risk of atherosclerosis in humans. *Arterioscler. Thromb. Vasc. Biol.*; 25: 279.

Mudd, S.H. (1964):

Homocystinuria: an enzymatic defect. *Science*; 143: 1443 – 5.

Mudd, S.H.; Finkelstein, J.D.; Refsum, H.; Ueland, P.M.; Malinow, M.R.; Lentz, S.R.; Jacobsen, D.W.; Brattstrom, L.; Wilcken, B. and Wilcken, D.E. (2000):

Homocysteine and its disulfide derivatives: a suggested consensus terminology. *Arterioscler. Thromb. Vasc. Biol.*; 20 : 1704 – 6.

Muller, F.; Svardal, A.M.; Aukrust, P.; Berge, R.K. Ueland, P.M. and Froland, S.S. (1996):

Elevated plasma concentration of reduced homocysteine in patients with human immunodeficiency virus infection. *Am. J. Clin. Nutr.*; 63 (2): 242 – 8.

Murray, C.J. and Lopez, A.D. (1997):

Mortality by cause for eight regions of the world: global burden of disease study. *Lancet.*; 349: 1269 – 76.

Nael, B.; MacMahon, S.; Ohkubo, T.; Tonkin, A.; Wilcken, D.; and Pacific Study Group (2002):

Dose-dependent effect of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals with coronary heart disease. *Eur. Heart J.*; 23 (19): 1509 – 15.

Nakano, E.; Higgings, J.A. and Powers, H.J. (2001):

Folate protects against oxidative modification of human LDL. *Br. J. Nutr.*; 86: 637 – 9.

Nappo, F.; De Rosa, N.; Marfella, R.; DeLucia, D.; Ingrosso, D.; Perna, A.F.; Farzati, B. and Giugliano, D. (1999):

Impairment of endothelial function by acute hyperhomocysteinemia and reversal by antioxidant vitamins. *JAMA*; 281 (22): 2113 – 8.

Narin, F.; Narin, N.; Akcakus, M.; Ustdal, M.; Karakucuk, I. and Halici, C. (2002):

The effect of folic acid, vitamin B6 and vitamin B12 on homocysteine level in rabbits fed by methionine-enriched diets. *Tohoko J. Exp. Med.*; 198 (2): 99 – 105.

Neaton, J.D. and Wentworth, D. (1992):

Serum cholesterol, blood pressure, cigarette-smoking and death from coronary heart disease: overall findings and differences by age for 316099 white men. *Arch. Intern. Med.*; 152: 56 – 64.

Nishio, E. and Watanabe, Y. (1997):

Homocysteine as a modulator of platelet derived growth factor action in vascular smooth muscle cells: a possible role for hydrogen peroxide. *Br. J. Pharmacol.*; 122 (2): 269 – 74.

Nygard, O.; Nordrehaug, J.E.; Refsum, H.; Ueland, P.N.; Farstad, M. and Vollset, S.E. (1997):

Plasma homocysteine levels and mortality in patients with coronary artery disease. *N. Engl. J. Med.*; 337: 230 –6.

Ortega, R.M.; Maas, L.R.; Andres, P.; Gaspar, M.J.; Agudo, F.R.; Jiemenez, A. and Pascual, T. (1996):

Functional and psychic deterioration in elderly people may be aggravated by folate deficiency. *J. Nutr.*; 126: 8, 1992 – 9.

Pandolfi, A.; Cetrullo, D.; Polishuck, R.; Alberta, M.M.; Calafiore, A.; Pellegrini, G.; Vitacolonna E.; Capani, F.; Consoli, A.(2001):

Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. *Arterioscler. Thromb. Vasc. Biol.*; 21(8): 1378 – 82.

Pederson, O.D.; Gram, G. and Jespersen, J. (1995):

Plasminogen activator inhibitor type determines plasmin formation in patients with ischemic heart disease. *Thromb. Haemost.*; 73: 835 – 40.

Peeters, A.C.; van der Molen, E.F.; Blom H.J. and den Heijer, M. (2004):

The effect of homocysteine reduction by B-vitamin supplementation on markers of endothelial dysfunction. *Thromb. Haemost.*; 92 (5): 1086 – 91.

Peterson, J.C. and Spence, J.D. (1998):

Vitamins and progression of atherosclerosis in hyperhomocysteinemia. *Lancet*; 451: 263.

Pfeiffer, C.M.; Rogers, L.M.; Bailey, L.B. and Gregory 3rd, J.F. (1997):

Absorption of folate from fortified cereal grain products and of supplemental folate consumed with or without food determined by using a dual label stable- isotope protocol. *Am. J. Clin. Nutr.*; 66: 6, 1388 – 97.

Picciano, M.F.; Stokstool, E.L.R.; Gregory, J.F. (1990):

Development of human folate deficiency. *Textbook of Folic Acid Metabolism in Health and Disease*. Vol. 13, P. 195 – 210.

Pinelli, A.; Trivulzio, S.; Tomasoni, L.; Benna, S.; Bonacina, E. and Accinni, R. (2004):

Isoproterenol-induced myocardial infarction in rabbits. Protection by propranolol or labetalol: a proposed non invasive procedure. *Eur. J. pharm. Sci.*; 23 (3): 277 – 85.

Pita, M.L. and Delgado, M.J. (2000):

Folate administration increases n-3 polyunsaturated fatty acids in rat plasma and tissue fluid. *Thromb. Haemost.*; 84 (3): 420 – 3.

Quere, I.; Habib, A.; Tobelem, G. and Maclouf, J. (1995):

Inhibition of cyclo-oxygenase activity in human endothelial cells by homocysteine. *Adv. Prostag. Thromb. Leuk. Res.*; 23: 397 – 9.

Rafflenbaul, W. (2005):

Homocysteine--risk factor or risk indicator. *MMW. Fortschr. Med.*; 147 (44): 28 – 30.

Rajadurai, M. and Prince P., S.M. (2007):

Preventive effect of naringin on cardiac markers, electrocardiographic patterns and lysosomal hydrolases in normal and isoproterenol-induced myocardial infarction in Wistar rats. *Toxicology.*; 230 (2-3):178 – 88.

Rakel, R.E. (1999):

Pernicious anemia and other megaloblastic anemias. Textbook Conn's Current Therapy. P. 579 – 87.

Ramsey, M.W.; Goodfellow, J.; Jones, C.J.H.; Luddington, L.A.; Lewis, M.J. and Henderson, A.H. (1995):

Endothelial control to arterial distensibility is impaired in chronic heart failure. *Circulation*; 92: 3212 – 19.

Rasmussen, K. and Moller, J. (2000):

Total homocysteine measurement in clinical practice. *Ann. Clin. Biochem.*, 37 (5): 627 – 48.

Ray, J.G. and Laskin, C.A. (1999):

Folic acid and homocysteine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss. A systematic review. *Placenta*; 20 (7): 519 – 29.

Redondo, M.; Watzke, H.H.; Stuck, B.; Saber, I.; Damarmels, Basiutti, F.; Binden, B.R.; Furlan, M.; Lammle, B. and Willemin, W.A. (1999):

Coagulation factors II, V, VII, X and Leiden factor in coronary artery disease. High factor V clotting activity is an independent risk for myocardial infarction. *Arterioscler. Thromb. Vasc. Biol.*; 19: 1020 – 5.

Refsum, H.; Ueland, P.M.; Nygard, O. and Vollset, S.E. (1998):

Homocysteine and cardiovascular disease. *Annu. Rev. Med.*; 49: 31 – 62.

Robinson, K.; Arheart, K.; Refsum, H.; Brattstrom, L.; Boers, G.; Ueland, P.; Rubba, P.; Palma-Reis, R.; Meleady, R.; Daly, L.; Writtemen, J. and Graham, I. (1998):

Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease and coronary artery disease: Europearn COMAC group. *Circulation*; 97: 437 – 43.

Robinson, K.; Mayer, E.L.; Miller, D.P.; Green, R.; Vanlente, F.; Gupta, A.; Kotte-Marchant, K.; Soven, R.; Sclhub, J.; Nissen, S.E.; Kutner, M.; Topel, E. J. and Jacobsen, D.W. (1995):
Hyperhomocysteinemia and low pyridoxal phosphate: common and independent reversible risk factor for coronary artery disease. *Circulation*; 92 (10): 2825 – 30.

Roebuck, A. and Farrer, M. (2006):

Identifying and managing acute coronary syndrome. *Nurs. Times.*; 102(6): 28 – 30.

Ross, R. (1993):

The pathogenesis of atherosclerosis: a prospective for the 1990s. *Nature.*; 362 (6423): 801 – 9.

Sabeena-Farvin, K.H.; Anandan, R.; Kumar, S.H.; Shiny, K.S.; Sankar, T.V. and Thankappan, T.K. (2004):

Effect of squalene on tissue defense system on isoproterenol induced myocardial infarction in rats. *Pharmacol. Res.*; 50 (3): 231 – 6.

Saltissi, S. and Mushahwar, S.S. (1995):

The management of acute myocardial infarction. *Postgrad. Med. J.*; 71 (839): 534 – 41.

Sebstjen, M.; Zegura, B.; Guize, Z. and Keber I. (2001):

Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous families hypercholesterolemia. Hypertension.; 15:11B (3-4): 13 – 18.

Selhub, J. (1999):

Hemocysteine metabolism. Annu. Rev. Nutr.; 19: 217 – 46.

Selhub, J. and Miller, J.W. (1992):

The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am. J. Clin. Nutr.; 55 (1): 131 – 8.

Selhub, J.; Jacques, P.E.; Wilson, P.W.; Rush, D. and Rosenberg, I.T. (1993):

Vitamin status and intakes as primary determinants of homocysteinemia in an elderly population. JAMA; 270: 2693 – 8.

Sesso, H.D.; Lee, I.M.; Gazian, J.M.; Rexrode, K.M.; Glynn, R.J. and Buring J.E. (2001):

Maternal and paternal history of myocardial infarction and cardiovascular risk of cardiovascular disease in men and women. Circulation.; 104: 393 – 8.

Sharma, A. and Singh, M. (2000):

Effect of isoproterenol amiloride, a Na^+/H^+ exchange inhibitor, on cardioprotective effect of ischemic and angiotensin preconditioning. Mol. Cell Biochem; 214: 31 – 8.

Shaw, G.M.; Velie, E.M.; Schaffer, D.M. (1997):

Is dietary intake of methionine associated with a reduction in risk for neural tube defects associated pregnancies?. *Teratology.*; 56: 295 – 9.

Shils, M.; Olson, J.A.; Schicke, M. and Ross, A.C. (1999):

Nutrition in health and disease. Textbook, 9th ed., p. 433 – 46.

Signorello, M.G.; Pascale, R. and Leoncini, G. (2002):

Effect of homocysteine on arachidonic acid release in human platelets. *Eur. J. clin. Invest.*; 23 (4) : 279 – 84.

Simmons, J.; Willens, J.H. and Kessler, K.M. (1995):

Acute myocardial infarction. Then and now. *Chest.*; 107: 1732 – 43.

Singhal, A.; Farooqi, S.; Cole, T.J.; O’Rahilly, S.; Fewtrell, M.; Kattenhorn, M.; Lucas, A. and Deanfield, J. (2002):

Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease. *Circulation.*; 106 (15): 1919 – 24.

Siri, P.W.; Verhoef, P. and Kok, F.J. (1998):

Vitamins B6, B12 and Folate: Association with plasma total homocysteine and risk of coronary atherosclerosis *J. Am. Coll. Nutr.*; 17 (5): 435 –41.

Smulders, Y.M. and Stehouwer, C.D. (2005):

Folate metabolism and cardiovascular disease. *Semin. Vasc. Med.*; 5(2): 87 – 97.

Solini, A.; Santini, E. and Ferrannini, E. (2006):

Effect of short- term folic acid supplementation on insulin sensitivity and inflammatory markers in overweight subjects. *Int. J. Obs.*; 100: 316.

Solomon, C.G.; Lee, T.H., Cook, E.F.; Weisberg, M.C.; Brand, D.A.; Rouan, G.W. and Goldman, L. (1989):

Comparison of clinical presentation of acute myocardial infarction in patients older than 65 years of age to younger patients: the multicenter chest pain study experience. *Am. J. Cardiol.*; 63: 772 – 6.

Splaver, A.; Lamas, G.A. and Hennekens, G.H. (2004):

Homocysteine and cardiovascular disease: biological mechanisms, observational epidemiology, and the need for randomized trials. *Am. Heart J.*; 148 (1): 34 – 40.

Stein, J.H. and McBride, P.E. (1998):

Hyperhomocysteinemia and atherosclerotic vascular disease: Pathophysiology, screening and treatment. *Arch. Intern. Med.*; 158(12): 1301 – 6.

Stroes, E.S.; Van Faassen, E.E.; Yo, M.; Martasek, P.; Boer, P.; Govers, R. and Rabelink, T.J. (2000):

Folic acid reverts dysfunction of endothelial nitric oxide synthase. *Circ. Res.*; 86: 1129 – 34.

Sun, P.; Dwyer, K.M.; Merz, N.B.; Sun, W.; Johnson, C.A.; Schircore, A.M. and Dwyer, J.H. (2000):

Blood pressure, LDL cholesterol and intima-media thickness. *Arterioscler. Thromb. Vasc. Biol.*;20: 2005.

Superko, H.R. (1997):

Elevated high density lipoprotein cholesterol, not protective in the presence of hyperhomocysteinemia. *Am. J. Cardiol.* 79: 705 – 6.

Swift, M.E. and Schultz, T.D. (1986):

Relationship of vitamin B6 and B12 to homocysteine levels: risk for coronary heart disease. *Nutr. Rep. Int.*; 34: 1 – 14.

Tasi, J.C.; percella, M.A.; Yoshizumi, M.; Hsich, C.M.; Haber, E.; Schlegel, R. and Lee, M.R. (1994):

Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. *Proc. Natl. Acad. Sci. USA*; 91: 6369 – 73.

Tawakol, A.; Migrine, R.Q.; Aziz, K.S.; Waitkowska, J.; Holmvang, G.; Alpert, N.M.; Muller J.E.; Fischman, A.J. and Gewirtz, H. (2005):

High dose folic acid acutely improves coronary vasodilator function in patients with coronary artery disease. *J. Am. Coll. Cardiol.*; 45 (10): 580 – 4.

Tawakol, A.; Omland, T.; Gerhard, M.; Wu, J.T. and Creager, M.A. (1997):

Hyperhomocysteinemia is associated with impaired endothelium-dependent vasodilatation in humans. *Circulation*; 95: 1119 – 21.

Teerlink, J.R.; Pfeffer, J.M. and Pfeffer, M.A. (1994):

Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. *Circ. Res.*; 75: 105 – 113.

Thogerson, A.M.; Jansson, J.H.; Boman, K.; Nilsson, T.K.; Weinehall, L.; Hutsaari, F. and Hallmans, G. (1998):

High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma proceed a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. *Circulation.*; 98: 2241.

Tiefenbacher, C.P.; Chilian, M.W. Mitchell, M. and Defily, D.V. (1996):

Restoration of endothelium dependent vasodilatation after reperfusion injury by tetrahydrobiopterin. *Circulation*; 94: 1423 – 9.

Toborek, D.F. and Hanratty, B. (1994):

Is methionine an atherogenic amino acid?. *J. Optimal Nutr.*; 3: 80-3.

Toborek, M.; Drozd, M. and Wieczorek, M. (1995):

Increased lipid peroxidation as a mechanism of methionine induced atherosclerosis in rabbits. *Atherosclerosis*; 115: 217 – 24.

Toole, J.F.; Malinow, M.R. and Chambless, L.E. (2004):

Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death: the vitamin intervention for stroke prevention (VISP) randomized control trial *JAMA*; 291: 565 – 75.

Townsend, J.H.; Davis, A.D.; Mackey, A.D. and Gregory III, J.F. (2004):

Folate deprivation reduces homocysteine remethylation in a human intestinal epithelial cell culture model: role of serine in one carbon donation. *Am. J. Physiol. (Gastrointest. Liver Physiol.)*; 286: G 588 – G 595.

Troen, A.M.; Lutgens, E.; Smith, D.E.; Rosenberg, I.H. and Selhub, J. (2003):

The atherogenic effect of excess methionine intake. *Proct. Nactl. Acad. Sci.*; 100 (25): 15089.

Tucker, K.L.; Selhub, J.; Wilson, P.W. and Rosenberg, I.H. (1996):

Dietary intake pattern relates to plasma folate and homocysteine concentrations in Framingham Heart Study. *J. Nutr.*;126: 3025 – 31.

Ubbink, J.B.; Vermaak, W.J.H.; Van der- Merwe, A.; Becker, P.J.; Delport, R. and Potgieter, H.C. (1994):

Vitamin requirements for the treatment of hyperhomocysteinemia in humans. *J. Nutr.*; 124: 1927 – 33.

Ueland, P.M.; Refsum, H.; Stabler, S.P. Malinow, M.R.; Anderson, A. and Allen, R.H. (1993):

Total homocysteine in plasma or serum: methods and clinical application. *Clin. Chem.*; 39: 1764 – 79.

Undas, A.; Domagala, T.B.; Jankowski, M. and Szczeklik, A. (1999):

Treatment of hyperhomocysteinemia with folic acid and vitamin B12 and B6 attenuates thrombin generation. *Thromb. Res.*; 95 (6): 281 – 8.

Ungvari, Z.; Sarkadi-Nagy, E.; Bagi, Z.; Szollar, L. and Koller, A. (2000):

Simultaneously increased TXA (2) activity in isolated arterioles and platelets of rats with hyperhomocysteinemia. *Arterioscler. Thromb. Vasc. Biol.*; 20 (5): 1203 – 8.

Upchurch, J.; G.R.; Welch, G.N.; Fabian, A.J.; Freedman, J.E.; Johnson, J.L.; Keaney Jr., J.F. and Loscalzo, J. (1997):

Homocysteine decreases bio-available nitric oxide by a mechanism involving glutathione peroxidase. *J. Biol. Chem.*; 272: 7012 – 7.

VanEde, A.E.; Laan, R.F.; Blom. H.J.; DeAbreu, R.A. and Vande Putte, L.B. (1998):

Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. *Semin. Arthritis Rheum.*; 27: 277 – 92.

Vasan, R.S.; Larson, M.g.; Kannd, W.B. and Levy, D. (2000):

Evolution of hypertension from non hypertensive blood pressure levels: rates of progression in Framingham Heart Study. J. Am. Coll. Cardiol.; 35: 292 A.

Verhoef, P. and deGroot, L.C. (2005):

Dietary determinants of plasma homocysteine concentrations. Semin. Vasc. Med.; 5 (2): 110 – 23.

Visser, M.; Bouter, L.M.; McQuillan, G.M.; Wener, M.H. and Harris, T. (1999):

Elevated C-reactive protein levels in over weight and obese adult. JAMA.; 282 (22): 2131 – 35.

Vita, J.A and Keaney Jr. J.F. (2002):

Endothelial function: a barometer for cardiovascular risk?. Circulation.; 106: 640 – 2.

Vivaldi, M.T.; Kloner, R.A. and Frederick, J.S. (1985):

Triphenyl tertezolium staining of irreversible ischemic injury following coronary artery occlusion in rats. Am. J. Pathol.; 121: 522 – 30.

VonEckardstein, A.; Malinow, M.R.; Upson, B.; Heinrich, J.; Schulte, H.; Schonfeld, R.; Kohler, E. and Assmann, G. (1994):

Effect of age, lipoproteins and haemostatic parameters on the role of homocysteinemia as a cardiovascular risk factor in men. Arterioscler. Thromb. Vasc. Biol.; 14: 460 – 4.

Vonhoute; P.M. and Boulanger, C.M. (1995):

Endothelium dependent response in hypertension. Hypertens. Res.; 18: 87 – 98.

Voutilainen, S.; Virtanen, J.K.; Rissanen, T.H.; Alfthan, G.; Laukkanen, J.; Mursu, J.; Volkonen, V.; Tuomainen, T.; Kaplan, G.A. and Salonen, J.T. (2004) :

Serum folate and homocysteine and the incidence of acute coronary events: the Kuopio Ischemic Heart Disease Risk Factor Study. *Am. J. Clin. Nutr.*; 80 (2): 317 – 23.

Wang, H.L.; Fan, D.S.; Shen, Y.; Sun, A.P.; Zhang, J. and Yang, (2005):

The relationship between carotid artery atherosclerosis and hyperhomocysteinemia. *Zhonghua Nei Ke Za Zhi.*; 44 (4): 258 – 61.

Wang, J.; Dudman, N.P.; Wilcken, D.E. and Lynch, J.F. (1992):

Homocysteine catabolism: levels of 3 enzymes in cultured human vascular endothelium and their relevance to vascular disease. *Arteriosclerosis*; 97: 97 – 106.

Washington, D.C. (1998):

Dietary reference intakes for thiamin, Riboflavin, Niacin, vitamin B6, Folate, Vitamin B12, pantothenic acid, Biotin and Choline. National Academy Press.; 196: 212 – 305.

Welch, G.N. and Loscalzo, J. (1998):

Homocysteine and atherothrombosis. *N. Engl. J. Med.*; 338: 1042- 50.

Wilcken, D.C. (1998):

Novel risk factors for vascular disease: the homocysteine hypothesis of cardiovascular disease. *J. Cardiovasc. Risk.*; 5 (4): 217 – 21.

Wilmink, H.W.; Stoes, E.S.; Erkelens, W.D.; Gerritsen, W.B.; Wever, R.; Banga, J.D. and Rabelink, T.J. (2000):

Influence of folic acid on postprandial endothelial dysfunction. *Arterioscler. Thromb. Vasc. Biol.*; 20: 185 – 8.

Wilson, P.W.; Kannel, W.B.; Silbershatz, H. and D'Agostion, R.B (1999):

Clustering of metabolic factors and coronary heart disease. Arch. Intern. Med.; 59: 1104 – 9.

Woo, K.S.; Sanderson, J.E. and Sun, Y.Y. (2000):

Hyperhomocysteinemia is a risk factor for arterial endothelial dysfunction in humans. Circulation; 101 : 116.

Woo, K.S; Chook, P.; Lolin, Y.I.; Cheung, A.S.P.; Chan, L.T.; Sun, Y.Y.; Sanderson, J.E. Metreweli, C. and Celermajer, D.S. (1997):

Hyperhomocysteinemia is a risk factor for arterial endothelial dysfunction in humans. Circulation; 96: 2542 – 44.

Wood, D.; Backer, G.D. and Faergeman, O. (1998):

Prevention of coronary heart disease in clinical practice: recommendations of the second joint task force of European and other Societies on coronary prevention. Eur. Heart J.; 19: 1434 – 1503.

Woodward, M.; Lowe, G.D.O.; Rumley, A. and Tunstall- peobe, E. (1998):

Fibrinogen as a risk factor for coronary heart disease and mortality in middle aged men and women: The Scottish Heart Health Study. Eur. Heart J.; 19: 55 – 62.

Wu, A.H.; Feng, Y.J.; Contois, J.H. and Pervaiz, S. (1996):

Comparison of myoglobin, creatine kinase-MB, and cardiac troponin I for diagnosis of acute myocardial infarction. Ann. Clin. Lab. Sci.; 26: 291 – 300.

Yang, F.; Tan, H.M. and Wang, W. (2005):

Hyperhomocysteinemia and atherosclerosis. Sheng Li Xue Bao.; 57 (2): 103 – 14.

Yogeeta, S.K.; Hanumantra, R.B.; Gnanapragasam, A.; Senthilkumar, S.; Subhashini, R. and Devaki, T. (2006):

Attenuation of abnormalities in the lipid metabolism during experimental myocardial infarction induced by isoproterenol in rats: beneficial role of ferulic acid and ascorbic acid. Basic clin. Pharmacol. Toxicol. 98 (5): 467– 72.

Zethelius, B.; Johnston, N. and Venge, P. (2006):

Troponin I as a predictor of coronary heart disease and mortality in 70 years old men: a community based cohort study. Circulation; 113(8): 1071– 9.

Zhang, R.; Ma, J.; Xia, M.; Zhu, H. and Ling, W. (2004):

Mild hyperhomocysteinemia induced by feeding rats diets rich in methionine or deficient in folate promotes early atherosclerosis. J. Nutr.; 134: 825 – 30.

Zhou, J.; Moller, J.; Danielsen, C.C.; Bentzon, J.; Ravn, H.B.; Austin, R.C. and Falk, E. (2001):

Dietary supplementation with methionine and homocysteine promotes early atherosclerosis but not plaque rupture in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol.; 21 (9): 1470 –6.

Zimetbaum, P.J and Josephson, M.E. (2003):

Use of the electrocardiogram in acute myocardial infarction. N. Engl. J. Med.; 348: 933 – 40.